Ipilimumab was approved for melanoma in 2013 and functions as an anti-CTLA-4 monoclonal antibody blocking downstream signaling and resulting in a more robust and prolonged T-cell-mediated immunity against melanoma tumor cells [30]. Here, CTLA4 is linked to neoplasm.